Financhill
Back

Oculis Holding AG Quote, Financials, Valuation and Earnings

Oculis Holding AG Price Quote

$17.15
+0.06 (+3.41%)
(Updated: December 14, 2024 at 4:08 AM ET)

Oculis Holding AG Key Stats

Sell
39
Oculis Holding AG (OCS) is a Sell

Day range:
$16.92 - $17.92
52-week range:
$9.60 - $18.00
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
0.00
P/B ratio:
6.15%

Volume:
132.5K
Avg. volume:
48.4K
1-year change:
54.52%
Market cap:
$695.7M
Revenue:
$0
EPS:
$-1.86

How Much Does Oculis Holding AG Make?

Data Unavailable

Is Oculis Holding AG Growing As A Company?

Data Unavailable

Oculis Holding AG Stock Price Performance

  • Did Oculis Holding AG Stock Go Up Last Month?
    Oculis Holding AG share price went up by 16.1% last month
  • Did OCS's Share Price Rise Over The Last Year?
    OCS share price rose by 54.52% over the past 1 year

What Is Oculis Holding AG 52-Week High & Low?

Oculis Holding AG Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Oculis Holding AG?

  • How Much Debt Does Oculis Holding AG Have?
    Total long term debt quarterly is $0
  • How Much Cash Does Oculis Holding AG Have?
    Cash and short term investments quarterly total is $125.4M
  • What Is Oculis Holding AG’s Book Value Per Share?
    Book value per share is 2.70

Is Oculis Holding AG Cash Flow Positive?

  • What Is OCS Cash Flow From Operations?
    Cash flow from operations (TTM) is -$56.7M
  • What Is Oculis Holding AG’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $57.5M
  • What Is Oculis Holding AG’s Cash Flow From Investing?
    Cash flow from investing (TTM) is $6.6M

Oculis Holding AG Return On Invested Capital

Data Unavailable

Oculis Holding AG Earnings Date & Stock Price

Oculis Holding AG Competitors

  • Who Are Oculis Holding AG's Competitors?
    Below is a list of companies who compete with Oculis Holding AG or are related in some way:
    • AC Immune SA (ACIU)
    • Addex Therapeutics Ltd (ADXN)
    • CRISPR Therapeutics AG (CRSP)
    • Molecular Partners AG (MOLN)
    • NLS Pharmaceutics Ltd (NLSP)

Oculis Holding AG Dividend Yield

Oculis Holding AG Analyst Estimates

YoY Growth Past Surprise
EPS: 0% -11.03%
Revenue: 0% -15.2%

Analyst Recommendations

Buy Recommendations: 5
Hold Recommendations: 0
Sell Recommendations: 0
Price Target: 28.54
Upside from Last Price: 67.01%

Major Shareholders

  • How many OCS shares are owned by institutional investors?
    12.6M OCS shares are owned by institutional investors
  • How many OCS shares are owned by insiders?
    0 OCS shares are owned by insiders